Glossary
FAP - Fibroblast activation protein TME - Tumour micro environnent
PREP - Prolyl endopeptidase - a protein coding gene HEK- Human embryonic kidney
HEK model - human embryonic kidney model, a cell line created for use in generating data
Xenograft - tissues transplanted from one species to another
PDX - Patient Derived Xenograft, which are models of cancer where the tissue or cells from a patient's tumour are implanted into a mouse.
HPAF-IIP - Human Pancreatic Adenocarcinoma cell line. WBC count - White blood cell count
PK - Pharmacokinetics
CAF - Cancer associated fibroblast Cleave - remove
Peptide - chain of amino acids that can bind to a warhead D-Ala-Pro - a peptide sequence providing exquisite selectivity for cleavage by FAPa
CGP-DOX - carboxybenzyl- Gly-Pro-doxorubicin, another modified version of doxorubicin
Osteosarcoma - a tumour of the bone
Cytotoxic - a substance or process that can damage cells or cause them to die
Anthracyclines - a class of drugs used in cancer chemotherapy Topoisomerases - enzymes that play essential roles in DNA replication
Neutropenia - a low number of white blood cells called neutrophils in the blood
Mucositis - when the mouth or gut is sore and inflamed Leukopenia - when the body doesn't have enough disease- fighting leukocytes in the blood
Febrile neutropenia - the development of a fever, alongside other signs of infection such as feeling unwell, shivers and shakes in a patient with neutropenia Thrombocytopenia - a deficiency of platelets in the blood. Cmax - maximum concentration
AUC - area under the curve (in this case showing overall exposure)
Undifferentiated pleomorphic sarcoma (UPS) - a type of cancer that begins mostly in the soft tissues of the body Angiosarcoma - a type of cancer that forms in the lining of the blood vessels and lymph vessels
Solitary fibrous tumours (SFT) - growths of cells that can form in almost any part of the body.
Minor response (MR): A patient qualifies as MR with a 10-29% reduction in the sum of the LD, taking as reference the baseline sum of the LD with non-progression.
Partial response (PR): Using a cancer imaging scan and RECIST v1.1 analysis, a patient qualifies as PR with at least a 30% reduction in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD and non- progression.
© Avacta Group plc 2024
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Avacta Group plc published this content on 05 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2024 15:39:01 UTC.